T1	Participants 85 147	immunization with hepatitis B surface antigen (HBsAg) vaccines
T2	Participants 341 448	50 subjects receiving four doses of hepatitis B vaccine according to a 0, 1, 2, 12 month vaccination scheme
T3	Participants 451 588	wenty-three subjects were given a plasma-derived vaccine (Hevac B) and 27 received a recombinant HBsAg vaccine (yeast-derived; Engerix-B)
T4	Participants 894 907	the vaccinees
